Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)

Last night, Broadfin Capital, a healthcare focused hedge fund managed by Kevin Kotler, disclosed in a Securities and Exchange Commission filing that it has initiated a 3.5 million share position in Pernix Therapeutics (NASDAQ:PTX), which amounts to a 9.4% stake in the specialty pharmaceutical company.

Kevin Kotler

The two other hedge fund managers tracked by us that are bullish on PTX are Samuel Isaly of Orbimed Advisors and Edward Gilhuly and Scott Stuart of Sageview Capital, who own 2.3 million shares (or a 6.3% stake) and 2.2 million (or a 6.0% stake), respectively. Interestingly, both Broadfin and Orbimed, who are now the two largest shareholders of Pernix Therapeutics (NASDAQ:PTX), focus on healthcare stocks, with the former investing primarily in smaller pharmaceutical and biotechnology micro-cap stocks and the latter investing across sub-industries and market caps within the healthcare space. This reflects the specialist knowledge and skillset required to invest in this industry, especially for smaller stocks.

Pernix Therapeutics (NASDAQ:PTX) is a $136.4 million market cap specialty pharmaceutical company that focuses on branded and generic products for the pediatric market. It develops products for allergy and upper respiratory, including nasal, chest congestion and cough, antibiotics, and dermatology. The company was founded in November 1996 and is headquartered in The Woodlands, TX. The stock, which is down 41% over the past 12 months, trades at a forward price / sales multiple of 1.3X and has been unprofitable, generating losses per share that missed consensus expectations for the past four quarters. Current estimates imply Pernix Therapeutics (NASDAQ:PTX) could break even for the full year 2014.

Kevin Kotler’s Broadfin Capital is located in New York City. Its portfolio consists of smaller stocks with market caps below $1 billion operating in the drug manufacturing / delivery, biotechnology, medical instruments / supplies / appliances / equipment, drug stores, healthcare plans and medical research. Before working with Broadfin, Kevin Kotler worked for The Galleon Group, ABN AMRO, and ING Barings. The fund has between $400 and $500 million in assets under management.

Disclosure: none

Recommended Reading:

Samuel Isaly Says He Is Fond of Regeneron Pharmaceuticals Inc (REGN) & InterMune Inc (ITMN)

Luxor Capital Group Raises Stake and Goes Activist on BJ’s Restaurants, Inc. (BJRI)

George Soros and Jeff Altman Are Both Betting On These Six Stocks

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!